TG Therapeutics Initiates BLA for Ublituximab Combo to Treat CLL
December 02, 2020

The company expects to complete the rolling submission of its biologics license application for ublituximab in combination with umbralisib in the first half of 2021.

FDA Grants Fast Track Designation to Irinotecan Liposome Injection for Second-Line Treatment of SCLC
December 01, 2020

The agency granted fast track designation to irinotecan liposome injection for patients with small cell lung cancer who progressed following a first-line platinum-based regimen.

FDA Approves Pralsetinib to Treat RET-Altered Thyroid Cancers
December 01, 2020

The FDA granted accelerated approval to pralsetinib to treat with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.